bovin
respiratori
syncyti
viru
brsv
major
caus
bronchiol
pneumonia
cattl
caus
yearli
outbreak
high
morbid
europ
commerci
vaccin
viru
need
improv
efficaci
especi
calv
brsvspecif
matern
deriv
antibodi
mda
previous
report
experiment
brsviscom
vaccin
commerci
vaccin
induc
strong
clinic
virolog
protect
calv
mda
immun
week
age
aim
present
studi
character
immun
respons
well
investig
efficaci
safeti
younger
anim
repres
target
popul
vaccin
four
group
five
week
old
calv
variabl
level
brsvspecif
mda
immun
sc
twice
week
interv
brsv
immunostimul
complex
brsviscom
ii
brsvprotein
iii
adjuv
iv
pb
calv
challeng
virul
brsv
aerosol
week
later
euthan
day
infect
cellular
humor
respons
monitor
well
clinic
sign
viral
excret
patholog
follow
challeng
despit
presenc
mda
time
immun
minimum
clinic
sign
observ
brsviscom
group
challeng
contrast
control
group
clinic
sign
diseas
observ
anim
respiratori
rate
min
rectal
temperatur
c
clinic
protect
associ
highli
signific
reduct
viru
replic
upper
lower
respiratori
tract
calv
rapid
system
local
antibodi
respons
helper
cell
respons
domin
product
anim
shed
viru
detect
pcr
cell
cultur
follow
challeng
possess
particularli
high
level
pulmonari
iga
protect
immunolog
respons
brsv
protein
abil
overcom
inhibit
effect
mda
depend
iscom
born
antigen
present
bovin
respiratori
syncyti
viru
brsv
member
pneumoviru
genu
paramyxovirida
famili
major
pathogen
respiratori
diseas
complex
cattl
viru
cytopathogen
directli
damag
respiratori
epithelium
vivo
also
induc
host
respons
contribut
develop
diseas
synergist
act
coor
superinfect
respiratori
pathogen
common
howev
clinic
sign
may
sever
infect
brsv
alon
diseas
pattern
brsv
cattl
popul
vari
accord
level
viru
circul
subsequ
eosinophil
lung
also
previous
observ
children
vaccin
human
h
rsv
fatal
outcom
two
infant
consequ
tragedi
although
hrsv
common
caus
acut
lower
respiratori
infect
children
frequent
caus
death
develop
countri
still
effect
hrsv
vaccin
avail
inde
new
vaccin
bovin
human
market
must
safe
also
ideal
design
induc
power
protect
immun
order
impact
viru
transmiss
complet
prevent
viru
replic
upon
infect
major
problem
achiev
goal
matern
deriv
antibodi
suppress
activ
respons
immun
even
moder
antibodi
level
per
se
protect
young
individu
rsv
diseas
age
infect
common
vaccin
cattl
prefer
perform
young
age
commingl
calv
larg
unit
brsv
often
circul
time
matern
antibodi
level
differ
calv
effici
level
popul
critic
new
vaccin
effect
face
matern
immun
nasal
administr
live
attenu
vaccin
recent
commerci
partial
protect
target
group
anim
howev
vaccin
viru
shed
long
period
confer
risk
passag
sentinel
calv
could
potenti
increas
virul
hand
inactiv
convent
brsv
vaccin
show
vari
efficaci
young
calv
brsv
field
furthermor
vaccin
rare
evalu
model
fulli
reproduc
clinic
sign
brsv
diseas
presenc
matern
antibodi
seldom
molecular
diagnost
tool
nevertheless
reduct
viru
shed
demonstr
follow
one
two
immun
challeng
brsv
induc
mild
diseas
previou
studi
use
virul
brsv
model
pcr
compar
efficaci
convent
inactiv
vaccin
experiment
vaccin
week
old
calv
matern
antibodi
except
result
convent
vaccin
poorli
protect
calv
matern
antibodi
wherea
experiment
vaccin
brsv
immunostimul
complex
brsviscom
confer
strong
clinic
well
nearli
complet
viral
protect
heterolog
brsv
strain
aim
present
studi
character
detail
protect
immun
respons
induc
brsviscom
young
anim
matern
antibodi
brsv
well
investig
efficaci
safeti
anim
repres
target
popul
vaccin
occas
vaccin
challeng
viru
homolog
time
vaccin
challeng
kept
short
approxim
situat
brsv
infect
commingl
young
calv
group
calv
immun
brsv
protein
without
adjuv
qualit
quantit
compar
iscom
includ
elucid
adjuv
effect
iscom
bovida
foetal
bovin
turbin
fbt
cell
vero
cell
propag
low
passag
dulbecco
modifi
eagl
medium
dmem
lonza
belgium
supplement
per
litr
ml
hepe
buffer
ml
mm
lglutamin
ml
nacl
solut
contain
mg
benzyl
penicillin
sodium
mg
streptomycin
sulfat
salt
well
foetal
calf
serum
fc
paa
laboratori
gmbh
austria
final
concentr
dmem
cell
test
free
bovin
viral
diarrhoea
viru
bvdv
immunoperoxidas
stain
use
polyclon
antisera
vla
uk
brsv
isol
denmark
propag
vero
cell
product
iscom
seventh
passag
brsv
isol
propag
fbt
cell
use
experiment
challeng
describ
earlier
aliquot
inoculum
titrat
well
challeng
calv
titer
determin
tcid
ml
respect
contamin
mycoplasma
could
detect
viru
determin
neg
cultur
within
routin
diagnost
nation
veterinari
institut
sweden
isoiec
viru
also
free
contamin
bvdv
bovin
coronaviru
bcov
bovin
parainfluenza
viru
determin
seroneg
bvdv
bcov
declin
antibodi
detect
enzymelink
immunosorb
assay
elisa
follow
two
brsviscom
vaccin
calv
brsv
challeng
furthermor
five
balbc
mice
remain
seroneg
bvdv
bcov
brsv
follow
two
vaccin
interv
data
shown
stock
solut
iscom
formul
prepar
dissolv
cholesterol
phosphatidylcholin
sigma
usa
concentr
mgml
distil
water
contain
ww
bachem
bubendorf
switzerland
quillaja
saponin
dessert
king
chile
dissolv
distil
water
concentr
mgml
stock
solut
kindli
provid
isconova
ab
uppsala
sweden
filter
filter
aliquot
kept
c
use
brsviscom
prepar
stock
purifi
solubil
brsv
briefli
sucros
gradient
purifi
brsv
mg
proteinml
solubil
wv
noctylglucosid
og
pb
boehring
mannheim
gmbh
frg
h
c
agit
solubil
viru
appli
onto
discontinu
sucros
gradient
ml
sucros
contain
og
ml
sucros
centrifug
g
rotor
beckman
coulter
min
c
sampl
volum
sucros
layer
contain
viral
protein
collect
cholesterol
phosphatidylcholin
well
quillaja
saponin
ad
proport
protein
cholesterol
phosphatidycholin
quillaja
saponin
calcul
weight
h
incub
room
temperatur
dialysi
perform
ammonium
acet
h
c
iscom
purifi
centrifug
sucros
g
rotor
beckman
coulter
h
c
steril
filtrat
brsv
protein
control
produc
accord
protocol
exclud
addit
cholesterol
phosphatidylcholin
quillaja
saponin
dialysi
adjuv
control
provid
isconova
ab
uppsala
sweden
made
batch
cholesterol
phosphatidylcholin
quillaja
saponin
use
brsviscom
dr
k
bengtsson
person
commun
twenti
conventionallyrear
calv
swedish
red
white
breed
swedish
holstein
breed
male
femal
age
week
obtain
close
dairi
herd
certifi
free
bvdv
bovin
leucosi
natur
brsv
infect
experiment
brsv
challeng
rule
regular
monitor
calv
well
five
seroneg
sentinel
anim
herd
brsvspecif
serum
antibodi
elisa
arriv
depart
clinic
scienc
swedish
univers
agricultur
uppsala
calv
treat
mg
toltrazurilkg
per
oral
rout
well
mgkg
procain
benzylpenicillin
intramuscularli
daili
five
day
minim
effect
concurr
infect
calv
match
four
group
accord
age
brsvspecif
serum
igg
level
hous
four
pen
fed
milk
replac
well
calf
pellet
twice
daili
addit
hay
water
ad
libitum
calv
left
unwean
throughout
studi
experi
approv
ethic
committe
univers
uppsala
sweden
ref
age
week
calv
immun
subcutan
sc
either
brsviscom
contain
g
total
protein
dilut
ml
pb
n
ii
brsvprotein
g
total
protein
dilut
ml
pb
n
iii
g
dilut
ml
pb
hereaft
call
adjuv
n
iv
ml
pb
n
twice
interv
week
mean
age
first
vaccin
day
brsviscom
brsv
protein
adjuv
pb
group
respect
two
week
second
vaccin
calv
challeng
ml
brsv
aerosol
inhal
super
dandi
inhailerboy
svevet
piab
sweden
challeng
procedur
carri
describ
tjornehoj
et
al
except
intratrach
inject
includ
order
group
calv
challeng
follow
brsviscom
brsv
protein
adjuv
pb
veterinarian
observ
calv
gener
local
advers
clinic
reaction
daili
basi
immun
perform
daili
clinic
examin
calv
post
infect
day
pid
pid
prior
procedur
pid
pid
calf
pulmonari
function
measur
forc
oscil
techniqu
hz
eem
hant
uk
pringl
et
al
prepar
clinic
sign
diseas
score
present
tabl
modifi
west
et
al
nasal
swab
virocult
medicalwir
equip
co
ltd
uk
obtain
indic
day
tabl
store
c
analys
brsvrna
realtim
quantit
rtpcr
rtqpcr
nasal
secret
obtain
use
tampon
left
one
nostril
min
ob
procomfort
tm
mini
sweden
pid
pid
upon
addit
ml
pb
tampon
recoveri
fluid
syring
sampl
store
c
analys
elisa
antibodi
serum
obtain
blood
collect
select
day
throughout
experi
peripher
blood
mononuclear
cell
pbmc
use
lymphoprolifer
cytokin
assay
extract
heparin
blood
collect
pid
well
pid
two
three
calv
per
group
day
challeng
describ
previous
pid
anim
euthan
gener
anesthesia
overdos
mgkg
ketamin
follow
mgkg
pentobarbit
sodium
exsanguin
lung
excis
visibl
macroscop
lesion
photograph
togeth
palpabl
lesion
record
standard
lung
diagram
lung
diagram
scan
convert
monochromat
represent
normal
lesion
lung
tissu
adob
photoshop
mac
use
complet
fill
lung
diagram
refer
lesion
percentag
calcul
digit
count
color
uncolor
pixel
unpublish
softwar
borland
delphi
sourc
code
request
author
bronchoalveolar
lavag
bal
perform
post
mortem
prepar
previous
describ
bal
cell
supernat
store
c
process
viru
isol
rtqpcr
antibodi
analysi
respect
tissu
sampl
three
site
three
lobe
right
lung
one
site
accessori
lobe
fix
neutralbuff
formalin
area
pneumon
consolid
present
alway
chosen
sampl
moreov
addit
sampl
homogen
dmem
store
c
prior
viru
isol
attempt
brsv
rna
analys
rtqpcr
detect
brsv
f
gene
accord
certif
ssen
iso
ssen
iso
within
routin
diagnost
nation
veterinari
institut
sweden
briefli
rna
extract
l
nasal
swab
medium
use
extract
robot
magnatrix
tm
vet
viral
na
kit
nordiag
sweden
rna
dissolv
l
rnasefre
water
qpcr
includ
revers
transcript
l
rna
carri
appli
biosystem
realtim
pcr
use
agpathid
tm
onestep
rtpcr
kit
appli
biosystem
sweden
previous
publish
primer
probe
rna
dilut
seri
extract
cell
cultur
contain
tcid
brsv
ml
includ
standard
pcr
run
brsv
standard
sampl
n
dilut
assign
valu
correl
tcid
accord
dilut
start
quantiti
unknown
sampl
express
unit
correl
tcid
accord
standard
curv
viru
isol
attempt
homogen
lung
tissu
bal
cell
inocul
onto
confluent
fbt
cell
cm
tissu
cultur
flask
describ
earlier
without
previou
steril
filtrat
daili
examin
cell
cultur
visibl
cytopath
effect
made
blind
manner
six
day
incub
neg
sampl
pass
second
time
new
set
cm
tissu
cultur
flask
igg
antibodi
brsv
sera
nasal
secret
bal
well
bvdv
bcov
igg
sera
analys
use
commerci
indirect
elisa
sampl
dilut
svanovir
svanova
biotech
sweden
accord
manufactur
instruct
addit
sera
collect
vaccin
serial
dilut
endpoint
titer
brsvspecif
matern
deriv
igg
tabl
effect
vaccin
brsv
infect
brsvspecif
matern
deriv
antibodi
detect
brsv
calv
identifi
calf
immun
brsviscom
n
brsv
protein
n
adjuv
n
pb
n
post
infect
day
pid
challeng
brsv
pid
brsviscom
calv
immunis
brsviscom
brsv
protein
adjuv
pb
challeng
brsv
day
b
brsvspecif
matern
deriv
igg
titer
nine
day
first
vaccin
c
calf
age
first
vaccin
express
day
nasal
swab
collect
indic
post
infect
day
pid
analys
brsv
rna
realtim
pcr
rna
quantifi
use
dilut
seri
brsv
known
standard
includ
run
e
bal
cell
inflam
lung
tissu
obtain
day
viru
isol
determin
visibl
cpe
turbin
cell
one
two
passag
cm
tissu
flask
visibl
cpe
two
passag
f
macroscop
patholog
lung
lesion
day
express
lesion
percentag
antibodi
calcul
linear
regress
endpoint
titer
given
reciproc
dilut
cutoff
correct
od
cod
valu
set
two
time
mean
cod
neg
control
serum
provid
kit
brsvspecif
igg
igg
antibodi
conjug
antibodi
kit
chang
follow
monoclon
antibodi
mous
antibovineigg
follow
rat
antimouseigg
hrp
detect
brsvspecif
igg
mous
antibovineigg
hrp
detect
brsvspecif
igg
antibodi
solut
ad
volum
l
per
well
incub
h
c
prior
three
wash
pbstween
solut
captur
elisa
use
detect
brsvspecif
iga
accord
uttenth
et
al
follow
modif
elisa
plate
maxisorp
nunc
tm
denmark
coat
h
c
mous
antibovineiga
block
h
c
pb
contain
wv
bsa
prior
addit
sampl
dilut
brsv
antigen
cell
control
mous
antibrsv
n
protein
mab
rat
antimouseigg
hrp
tmb
substrat
h
antibodi
antigen
solut
ad
volum
l
per
well
incub
h
c
prior
three
wash
pbstween
solut
cod
valu
calcul
subtract
absorb
valu
nm
well
contain
control
antigen
well
contain
brsv
antigen
data
express
percentag
cod
posit
control
sera
monoclon
antibodi
specif
bovin
ig
isotyp
obtain
abdserotec
uk
pbmc
obtain
anim
describ
section
restimul
triplic
well
brsv
antigen
prepar
frozen
thaw
fbt
cell
infect
brsv
denmark
ident
uninfect
cell
lysat
describ
previous
cod
valu
calcul
brsv
control
stimul
pbmc
six
day
incub
c
addit
alamar
blue
reagent
invitrogen
sweden
h
prior
measur
absorb
spectrophotometri
accord
manufactur
instruct
method
count
viabl
cell
previous
shown
reliabl
sensit
radioact
method
pbmc
obtain
anim
describ
section
screen
presenc
mrna
well
rrna
rtqpcr
brsv
stimul
pbmc
per
calf
h
c
cell
centrifug
g
supernat
remov
total
rna
extract
cell
use
rneasi
mini
kit
qiagen
sweden
rna
puriti
verifi
use
spectrophotometri
picodrop
ltd
uk
od
rna
sampl
store
c
analys
rtqpcr
use
iscript
onestep
rtpcr
kit
probe
biorad
sweden
qpcr
machin
biorad
sweden
previous
publish
standard
primer
probe
design
exclud
amplif
genom
dna
sampl
analys
duplic
rrna
triplic
mrna
mrna
result
given
relat
rrna
fixat
lung
tissu
sampl
calf
paraffin
wax
embed
section
stain
haematoxylineosin
accord
luna
method
detect
eosinophil
granul
section
assess
without
prior
knowledg
anim
treatment
inflammatori
chang
lung
lobe
score
normal
mild
moder
sever
data
analys
use
minitab
statist
softwar
use
anova
follow
dunnett
test
squar
root
valu
otherwis
specifi
statist
signific
set
p
p
p
contrast
brsv
protein
alon
adjuv
alon
pb
experiment
brsviscom
vaccin
use
immun
cattl
induc
clinic
protect
virul
brsv
challeng
fig
signific
reduct
mean
clinic
score
anim
immun
brsviscom
vs
immun
adjuv
alon
pid
p
clinic
respiratori
sign
observ
major
anim
receiv
adjuv
pb
character
moder
mark
mucopurul
nasal
discharg
wheez
sound
lung
auscult
tachypnea
spontan
cough
howev
one
calf
adjuv
group
markedli
affect
gener
condit
day
experi
termin
calf
pid
day
maximum
rectal
temperatur
respiratori
rate
per
minut
group
c
agreement
clinic
sign
anim
immun
brsviscom
averag
less
extens
lung
lesion
brsv
challeng
compar
control
fig
tabl
mean
area
macroscop
lung
lesion
significantli
less
anim
immun
brsviscom
vs
immun
pb
p
similar
tendenc
observ
vs
adjuv
group
p
analys
student
ttest
twotail
assum
equal
varianc
anova
anim
immun
brsv
protein
alon
also
tend
less
gross
patholog
lesion
compar
calv
immun
pb
differ
statist
signific
p
student
ttest
correl
found
clinic
sign
gross
patholog
anim
brsviscom
adjuv
pb
group
compar
individu
percentag
macroscop
patholog
lung
lesion
sum
clinic
score
pid
pearson
r
calv
immun
brsviscom
brsv
protein
adjuv
pb
respect
upon
histolog
examin
calv
show
sign
bronchointerstiti
pneumonia
one
sever
tissu
section
fig
inflammatori
pattern
anim
vari
mild
nonspecif
inflammatori
chang
sever
bronchointerstiti
pneumonia
consolid
parenchyma
mark
lymphoid
peribronchi
cuf
well
presenc
neutrophil
cellular
debri
bronchibronchioli
alveoli
sever
inflammatori
respons
ten
sampl
area
per
calf
lowest
brsviscom
group
mean
rank
compar
brsv
protein
adjuv
pb
group
respect
p
kruskalw
test
differ
signific
cranial
lobe
p
kruskalw
test
anim
neutrophil
compon
inflamm
promin
least
one
tissu
section
one
anim
belong
brsviscom
group
calf
e
extent
macroscop
lesion
three
brsv
protein
group
five
adjuv
group
four
pb
group
calf
worst
clinic
sign
also
sever
histopatholog
chang
mark
neutrophil
respons
calf
adjuv
group
though
eosinophil
sometim
present
inflam
tissu
constitut
major
fig
score
pulmonari
histopatholog
vaccin
calv
follow
challeng
brsv
calv
immun
describ
fig
microscop
lung
lesion
determin
pid
peribronchiolar
lymphocyt
absenc
bronchiol
alveol
calf
brsviscom
group
score
mild
b
moder
infiltr
inflammatori
cell
alveolar
wall
septa
small
amount
cellular
debri
present
bronchioli
focal
hyperplasia
peribronchiolar
lymph
inflammatori
cell
type
differ
eosinophilia
detect
differ
group
strong
reduct
nasopharyng
viral
excret
observ
calv
immun
brsviscom
compar
group
calv
tabl
remark
viral
rna
detect
rtqpcr
nasal
swab
two
five
anim
immun
brsviscom
calv
b
c
wherea
detect
control
includ
immun
brsv
protein
alon
pid
end
experi
pid
expect
day
peak
viru
shed
reduct
nasopharyng
viral
excret
anim
immun
brsviscom
statist
significantli
differ
immun
brsv
protein
p
pid
adjuv
p
pid
pb
p
pid
kruskalw
test
mean
quantiti
viral
rna
detect
pid
express
tcid
equival
unit
sd
anim
immun
brsviscom
brsv
protein
adjuv
pb
respect
surprisingli
calv
control
group
shed
highest
quantiti
viru
also
highest
level
brsvspecif
matern
deriv
igg
antibodi
challeng
calv
g
q
tabl
fig
mean
quantiti
brsv
rna
detect
bal
cell
pid
log
tcid
equival
copi
anim
brsviscom
brsv
protein
adjuv
pb
group
respect
one
sampl
protein
adjuv
group
calv
j
n
quantifi
howev
due
insuffici
rna
materi
analysi
agreement
rtqpcr
data
anim
immun
brsviscom
strongli
reduc
quantiti
live
viru
lung
determin
viru
isol
attempt
bal
lung
tissu
pid
tabl
brsv
isol
one
five
anim
immun
brsviscom
bal
cell
second
viru
passag
calf
c
wherea
isol
possibl
bal
cell
control
lung
tissu
control
first
viru
passag
declin
brsvspecif
matern
deriv
igg
antibodi
observ
first
sampl
vaccin
calv
immun
brsviscom
brsv
protein
end
studi
adjuv
pb
control
demonstr
absenc
natur
brsvinfect
fig
calv
one
calf
brsvspecif
matern
deriv
igg
antibodi
vaccin
titer
vari
tabl
advers
immunolog
reaction
observ
first
vaccin
despit
care
clinic
examin
convers
h
second
vaccin
anim
immun
brsviscom
adjuv
alon
develop
local
reaction
flat
swell
hand
palm
size
increas
rectal
temperatur
c
remain
h
anim
continu
good
appetit
milk
pellet
period
reaction
observ
anim
immun
brsv
protein
pb
rectal
temperatur
remain
normal
signific
differ
calf
bodyweight
first
vaccin
daili
weight
gain
first
vaccin
aggreg
calf
p
pb
group
score
moder
c
bronchointerstiti
pneumonia
consolid
parenchyma
mark
inflammatori
peribronchi
cuf
presenc
neutrophil
cellular
debri
bronchibronchioli
alveoli
calf
k
adjuv
group
score
sever
challeng
differ
immun
group
neither
anova
student
ttest
data
shown
formul
brsv
antigen
brsviscom
requir
induct
serum
igg
respons
singl
inject
fig
inde
brsvspecif
serum
igg
tend
increas
prime
four
five
anim
immun
brsviscom
none
anim
immun
brsv
protein
furthermor
strong
igg
respons
induc
anim
immun
brsviscom
rapidli
boost
contrast
weak
respons
induc
two
five
anim
immun
brsv
protein
alon
sera
pid
pid
verifi
brsvspecif
iga
igg
igg
elisa
fig
significantli
higher
iga
igg
igg
respons
detect
serum
anim
immun
brsviscom
compar
control
iga
pid
p
igg
igg
pid
p
within
brsviscom
group
calf
show
weakest
serum
igg
respons
although
individu
high
serum
level
igg
high
brsvspecif
lymphocyt
prolifer
respons
challeng
fig
calf
one
group
develop
fever
challeng
c
pid
shed
detect
viru
tabl
significantli
higher
level
brsvspecif
iga
igg
detect
nasal
fluid
anim
immun
brsviscom
compar
control
group
iga
pid
p
igg
pid
p
fig
calv
immun
brsviscom
shed
detect
viru
largest
decreas
nasal
igg
challeng
calv
b
c
fig
brsvspecif
iga
igg
furthermor
detect
lung
pid
fig
level
significantli
greater
anim
immun
brsviscom
iga
igg
p
brsviscom
group
mean
ratio
iga
igg
bal
rang
wherea
opposit
found
nose
mean
ratio
pid
respect
pid
rang
pid
rang
three
calv
highest
level
iga
bal
calv
viru
detect
nasal
swab
calf
e
fig
tabl
complet
iscom
formul
also
requir
induct
brsvspecif
lymphocyt
prolif
respons
challeng
fig
two
day
challeng
brsvspecif
tcell
prolifer
detect
two
five
calv
immun
brsviscom
control
group
significantli
differ
fig
howev
four
day
challeng
lymphocyt
four
five
anim
brsviscom
group
prolifer
restimul
vitro
brsv
antigen
contrast
brsvspecif
lymphocyt
prolif
respons
detect
control
calv
calv
immun
brsv
protein
alon
result
reproduc
use
two
addit
dilut
brsv
antigen
restimul
test
triplic
sampl
data
shown
lymphocyt
anim
sampl
occas
prolifer
stimul
concanavalin
demonstr
cell
viabil
cod
rang
increas
mrna
express
detect
brsvstimul
pbmc
obtain
calv
immun
complet
iscom
fig
h
stimul
brsv
antigen
pbmc
collect
challeng
brsviscom
immun
anim
contain
significantli
mrna
per
refer
gene
compar
collect
anim
immun
adjuv
pb
p
p
also
significantli
stronger
induct
mrna
pbmc
anim
immun
brsviscom
compar
immun
brsv
protein
p
mrna
level
averag
time
higher
among
anim
immun
brsviscom
howev
significantli
differ
ratio
among
control
averag
brsvprotein
adjuv
pb
similar
pattern
observ
pbmc
collect
boost
challeng
addit
within
brsviscom
group
individu
level
mrna
correl
perfectli
degre
virolog
protect
standard
data
shown
paper
demonstr
highli
signific
protect
induc
brsviscom
despit
presenc
brsvspecif
matern
antibodi
time
vaccin
thu
extend
previou
find
calv
old
calv
repres
relev
target
popul
brsv
vaccin
support
earlier
data
brsviscom
provid
clinic
protect
highli
signific
reduct
viru
excret
upper
respiratori
tract
calv
associ
rapid
system
nasal
antibodi
respons
addit
virolog
protect
lower
respiratori
tract
associ
local
system
humor
respons
well
cell
respons
domin
product
moreov
studi
safeti
experiment
vaccin
clinic
patholog
investig
absenc
clinic
sign
charact
pulmonari
cellular
respons
upon
succeed
virul
brsv
infect
without
excess
neutrophil
eosinophil
indic
good
safeti
brsviscom
vaccin
although
fig
brsvspecif
antibodi
respons
nasal
fluid
vaccin
calv
calv
identifi
calf
immun
describ
fig
challeng
brsv
pid
nasal
fluid
obtain
tampon
pid
dark
grey
bar
pid
light
grey
bar
tampon
wash
ml
pb
sampl
dilut
analysi
elisa
iga
igg
b
correct
od
cod
valu
present
percent
posit
refer
sera
confirm
includ
group
anim
immun
brsv
protein
alon
show
protect
immunolog
respons
protein
depend
iscom
born
antigen
present
brsviscom
induc
strong
protect
calv
age
like
suscept
brsv
infect
protect
difficult
achiev
age
anim
first
immun
extend
week
week
present
studi
accord
previou
experi
use
experiment
model
clinic
sign
observ
control
mimick
observ
natur
brsv
infect
field
includ
fever
tachypnea
individu
matern
antibodi
challeng
previous
report
natur
experiment
brsv
infect
clinic
sign
diseas
vari
within
control
group
standard
deviat
use
illustr
variat
instead
standard
error
mean
often
misus
purpos
variat
clinic
sign
patholog
might
due
short
time
challeng
euthanasia
result
variat
time
need
develop
diseas
probabl
influenc
factor
three
control
calv
sever
tachypnea
gross
patholog
also
highest
level
brsvspecif
matern
igg
challeng
highest
viral
load
nasal
secret
within
group
among
oldest
youngest
support
suggest
matern
antibodi
fulli
protect
tcell
andor
mucos
antibodi
respons
play
import
role
protect
hypothet
sever
diseas
three
control
calv
could
link
individu
genet
variat
respons
brsv
infect
suggest
case
hrsv
anim
viral
infect
calv
identifi
calf
immun
describ
fig
challeng
brsv
pid
peripher
blood
mononuclear
cell
obtain
pid
challeng
dark
grey
bar
pid
challeng
light
grey
bar
stimul
brsv
control
antigen
prolifer
express
correct
od
valu
mean
triplic
six
day
stimul
addit
alamar
blue
reagent
contrast
control
anim
immun
brsviscom
protect
clinic
sign
diseas
clinic
score
support
lung
function
measur
forc
oscil
method
origin
evalu
calv
use
bronchomodulatori
treatment
could
potenti
use
improv
object
clinic
assess
respiratori
infect
model
calv
discuss
elsewher
pringl
et
al
prepar
abil
brsviscom
induc
effici
clinic
protect
follow
brsv
challeng
associ
highli
signific
virolog
protect
upper
lower
respiratori
tract
sever
anim
possess
brsvspecif
matern
antibodi
time
first
immun
appear
complet
protect
sinc
nasal
viru
shed
detect
rtqpcr
techniqu
chosen
increas
viru
detect
sensit
compar
vaccin
evalu
brsv
seroposit
calv
use
viru
isol
alon
inde
high
quantiti
viral
rna
found
respiratori
sampl
control
repeat
demonstr
limit
viru
shed
brsviscom
immun
anim
inevit
led
question
whether
viral
replic
complet
prevent
certain
anim
challeng
data
present
herein
evid
replic
occur
although
low
level
viral
rna
detect
bal
brsviscom
immun
anim
six
day
inocul
moreov
one
anim
harbor
live
viru
lung
although
contrast
control
detect
first
viru
passag
eas
viru
isol
control
highlight
virul
challeng
remain
investig
low
amount
viru
detect
brsviscom
group
would
transmit
sentinel
data
suggest
brsviscom
would
impact
brsv
transmiss
field
must
new
brsv
vaccin
candid
effici
also
safe
advers
reaction
brsviscom
adjuv
group
upon
boost
similar
extent
observ
commerci
cattl
vaccin
reaction
probabl
link
quillaja
saponin
compon
increas
time
lipid
protein
compar
previous
besid
caus
direct
toxic
acut
hypersensit
reaction
brsv
vaccin
must
induc
exagger
inflammatori
respons
upon
natur
infect
inde
problem
vaccin
brsv
cattl
close
relat
hrsv
man
formalin
inactiv
fi
hrsv
vaccin
induc
sever
pulmonari
neutrophilia
children
presenc
eosinophil
fatal
case
vaccin
induc
enhanc
diseas
reproduc
experiment
mice
cattl
reduc
product
even
promin
pulmonari
eosinophilia
small
anim
model
fihrsv
induc
immun
respons
may
respons
bronchoconstrict
inflamm
follow
rsv
infect
review
castilow
varga
meyer
et
al
although
mild
clinic
sign
diseas
record
iscom
immun
calv
brsv
challeng
necessari
character
pulmonari
inflammatori
respons
provid
strong
limit
viral
replic
highlight
chen
et
al
observ
virolog
protect
associ
peribronchiolari
inflamm
increas
eosinophil
bal
hrsviscom
immun
mice
hrsv
challeng
clinic
sign
diseas
report
studi
vaccin
protocol
challeng
model
induc
influx
leucocyt
limit
area
lung
virul
brsv
challeng
howev
increas
number
cell
observ
compar
control
deeper
character
pulmonari
cellular
respons
infect
iscomimmun
anim
present
ongo
immunolog
respons
investig
herein
sever
approach
previou
experi
system
local
humor
respons
rapid
strong
boost
four
five
anim
show
antibodi
respons
singl
inject
furthermor
limit
viru
detect
iscom
immun
anim
associ
prevaccin
passiv
antibodi
statu
iscom
capac
overcom
matern
immun
confirm
although
one
major
problem
vaccinolog
relev
broad
rang
pathogen
exact
mechan
respons
inhibitori
effect
matern
deriv
antibodi
activ
immun
still
fulli
understood
clear
howev
inhibit
determinantspecif
occur
primarili
bcell
probabl
antibodi
mask
epitop
vaccin
antigen
prevent
bind
cell
possibl
also
interfer
antigen
uptak
present
although
cellular
respons
much
less
affect
humor
respons
notabl
even
brsv
specif
tcell
memori
induc
presenc
matern
antibodi
calv
antibodi
respons
induc
commerci
vaccin
previou
studi
commonli
absent
induc
clinic
protect
poor
model
reproduc
clinic
sign
diseas
observ
field
mechan
iscom
overcom
inhibit
effect
matern
antibodi
unknown
one
possibl
effect
due
antigen
dose
relat
level
matern
antibodi
howev
describ
detail
elsewher
et
al
prepar
one
dose
brsviscom
contain
less
g
brsv
protein
time
less
subunit
brsv
vaccin
administ
calv
nevertheless
given
weak
respons
induc
brsv
protein
alon
presenc
antigen
form
iscom
particl
andor
effect
adjuv
compon
essenti
present
investig
whether
incorpor
brsvprotein
iscom
requir
altern
whether
similar
immunogen
obtain
antigen
mix
commerci
avail
preform
empti
iscom
anoth
adjuv
capac
iscom
prime
rapid
iga
product
challeng
confirm
previous
shown
serum
bal
nasal
fluid
immun
challeng
anim
similarli
long
last
pulmonari
iga
induc
intranas
brsviscom
immun
mice
contrast
low
level
pulmonari
igg
detect
bal
probabl
due
high
dilut
sampl
suggest
iga
activ
transport
lung
present
high
amount
two
calv
iscom
group
shed
detect
amount
viru
lowest
level
pulmonari
brsvspecif
iga
within
group
although
iga
relat
cytokin
mice
presenc
iscom
vaccin
skew
immun
respons
calv
toward
confirm
earlier
public
thu
contrast
calv
immun
brsv
protein
alon
anim
immun
brsviscom
rapidli
acquir
serum
igg
immunoglobulin
associ
cytokin
furthermor
similar
pattern
seen
induct
igg
mice
data
shown
sinc
igg
igg
assay
normal
differ
posit
control
sera
possibl
compar
concentr
paramet
howev
bear
mind
four
month
age
calv
normal
similar
level
total
igg
adult
cattl
wherea
total
igg
half
adult
level
igg
complement
activ
presenc
antibodi
isotyp
might
link
protect
associ
strong
tcell
respons
power
antibodi
respons
probabl
associ
abil
iscom
induc
strong
balanc
thelper
cell
respons
assess
restimul
pbmc
kill
antigen
ex
vivo
antigen
present
mhc
ii
memori
helper
cell
stimul
pbmc
brsviscom
immun
anim
show
significantli
higher
level
mrna
per
cell
control
time
higher
level
mrna
addit
significantli
higher
lymphocyt
prolif
respons
induc
anim
immun
brsviscom
indic
lymphocyt
would
undergo
effici
clonal
expans
produc
cytokin
per
cell
upon
brsv
infect
remain
verifi
vivo
bovin
gener
associ
enhanc
bcell
surviv
igg
antibodi
product
cattl
wherea
normal
link
type
respons
product
igg
activ
macrophag
well
cytotox
lymphocyt
ctl
review
est
brown
iscom
previous
shown
except
capac
induc
ctl
respons
possibl
enabl
bcell
crosspresent
kill
antigen
lymphocyt
investig
brsv
futur
supposedli
mark
moder
mrna
induct
promot
iscom
induct
type
interferon
bovin
vitro
system
shown
induc
igg
also
iga
product
addit
upregul
product
iga
secretori
compon
iga
transcytosi
human
bronchial
epitheli
cell
vitro
summari
brsviscom
effici
inactiv
vaccin
mimic
natur
brsv
infect
strongli
prime
product
mrna
lymphocyt
local
well
system
immun
particularli
strong
iga
pulmonari
respons
without
diseas
enhanc
effect
